The trial, which treated 12 patients in The Netherlands, evaluated RPL554 for a period of 6 days with daily doses in patients with mild asthma.
The trial results showed that RPL554 had sustained bronchodilator actions throughout the treatment period.
Further, there was no accumulation of the drug in plasma and no safety issues were observed.
Verona CEO Michael Walker said the clinical studies performed so far with RPL554 have defined the actions of their drug in terms of doses that are safe and produce a clear and unequivocal bronchodilator effect.
"The sustained bronchodilator effect of RPL554 throughout the treatment period is an important finding, and one that we will use when selecting the dosing regimen for a further trial we are currently planning to demonstrate unequivocally the anti-inflammatory actions of RPL554," Walker said.